At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 and 2 Clinical Trial of ALIMTA® (Pemetrexed) in Combination With Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer
In Brief
A Phase 2 clinical trial evaluating Pemetrexed - Phase 1, Carboplatin - Phase 1, and 2 other interventions for Ovarian Cancer and Primary Peritoneal Cancer. Completed, enrolled 86 participants across 22 sites in 5 countries.
Detailed Summary
The purpose of this study is to determine efficacy of the combination therapy of pemetrexed and carboplatin as treatment for patients with platinum-sensitive ovarian cancer. This study also includes patients with primary peritoneal cancer.
Study Details
Timeline
Interventions
500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles